Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance

Levosimendan is a calcium sensitizer used for managing heart failure (HF) because of its inotropic and vasodilatory effects. As many patients do not respond to levosimendan as a monotherapy, it may be necessary to combine it with other diuretic agents such as recombinant human brain natriuretic pept...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shen Xiangli, Li Lan, Zu Libiya, Ma Jun, Jiang Shubin
Formato:	article
Lenguaje:	EN
Publicado:	Taylor & Francis Group 2021
Materias:	volume overload dyspnea score heart disease inotropic effect combination diuretic therapy Medicine R
Acceso en línea:	https://doaj.org/article/34a08f3629df49b3850369cf36f3b1f8
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:34a08f3629df49b3850369cf36f3b1f8
record_format	dspace
spelling	oai:doaj.org-article:34a08f3629df49b3850369cf36f3b1f82021-11-26T11:19:48ZEffect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance1993-28201819-635710.1080/19932820.2021.1973762https://doaj.org/article/34a08f3629df49b3850369cf36f3b1f82021-01-01T00:00:00Zhttp://dx.doi.org/10.1080/19932820.2021.1973762https://doaj.org/toc/1993-2820https://doaj.org/toc/1819-6357Levosimendan is a calcium sensitizer used for managing heart failure (HF) because of its inotropic and vasodilatory effects. As many patients do not respond to levosimendan as a monotherapy, it may be necessary to combine it with other diuretic agents such as recombinant human brain natriuretic peptide (rhBNc P). The aim of this study was to investigate efficacy of levosimendan when combined with rhBNP in patients with diuretic resistance and low ejection fraction (EF) rate. The study included HF patients with diuretic resistance and low EF. Before grouping, patients with a 24-hour urine volume of <0.5 mL/kg/h were administered with furosemide injection. Treatment group was administered levosimendan injection based on the original diuretic and rhBNP. One hundred twenty-eight patients were included, with 64 patients each in the control and treatment arms. 24-hour urine volume of the treatment group was significantly higher than that of the control group. Moreover, dyspnea score of the treatment group significantly improved compared with control group. In the treatment group, 12.5% of patients had no significant changes in the urine volume, weight, and dyspnea score before and after the treatment, indicating poor curative effect of the treatment, whereas in the control group, 23.4% of patients had poor curative effect (P < .05). No significant change was observed in the systolic blood pressure, heart rate, and serum creatinine level before and after treatment in both groups. Levosimendan in combination with rhBNP can effectively relieve diuretic resistance, reduce body weight, improve dyspnea, and ensure safety in the treatment process.Shen XiangliLi LanZu LibiyaMa JunJiang ShubinTaylor & Francis Grouparticlevolume overloaddyspnea scoreheart diseaseinotropic effectcombination diuretic therapyMedicineRENLibyan Journal of Medicine, Vol 16, Iss 1 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	volume overload dyspnea score heart disease inotropic effect combination diuretic therapy Medicine R
spellingShingle	volume overload dyspnea score heart disease inotropic effect combination diuretic therapy Medicine R Shen Xiangli Li Lan Zu Libiya Ma Jun Jiang Shubin Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance
description	Levosimendan is a calcium sensitizer used for managing heart failure (HF) because of its inotropic and vasodilatory effects. As many patients do not respond to levosimendan as a monotherapy, it may be necessary to combine it with other diuretic agents such as recombinant human brain natriuretic peptide (rhBNc P). The aim of this study was to investigate efficacy of levosimendan when combined with rhBNP in patients with diuretic resistance and low ejection fraction (EF) rate. The study included HF patients with diuretic resistance and low EF. Before grouping, patients with a 24-hour urine volume of <0.5 mL/kg/h were administered with furosemide injection. Treatment group was administered levosimendan injection based on the original diuretic and rhBNP. One hundred twenty-eight patients were included, with 64 patients each in the control and treatment arms. 24-hour urine volume of the treatment group was significantly higher than that of the control group. Moreover, dyspnea score of the treatment group significantly improved compared with control group. In the treatment group, 12.5% of patients had no significant changes in the urine volume, weight, and dyspnea score before and after the treatment, indicating poor curative effect of the treatment, whereas in the control group, 23.4% of patients had poor curative effect (P < .05). No significant change was observed in the systolic blood pressure, heart rate, and serum creatinine level before and after treatment in both groups. Levosimendan in combination with rhBNP can effectively relieve diuretic resistance, reduce body weight, improve dyspnea, and ensure safety in the treatment process.
format	article
author	Shen Xiangli Li Lan Zu Libiya Ma Jun Jiang Shubin
author_facet	Shen Xiangli Li Lan Zu Libiya Ma Jun Jiang Shubin
author_sort	Shen Xiangli
title	Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance
title_short	Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance
title_full	Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance
title_fullStr	Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance
title_full_unstemmed	Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance
title_sort	effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance
publisher	Taylor & Francis Group
publishDate	2021
url	https://doaj.org/article/34a08f3629df49b3850369cf36f3b1f8
work_keys_str_mv	AT shenxiangli effectoflevosimendancombinedwithrecombinanthumanbrainnatriureticpeptideondiureticresistance AT lilan effectoflevosimendancombinedwithrecombinanthumanbrainnatriureticpeptideondiureticresistance AT zulibiya effectoflevosimendancombinedwithrecombinanthumanbrainnatriureticpeptideondiureticresistance AT majun effectoflevosimendancombinedwithrecombinanthumanbrainnatriureticpeptideondiureticresistance AT jiangshubin effectoflevosimendancombinedwithrecombinanthumanbrainnatriureticpeptideondiureticresistance
_version_	1718409458857541632

Effect of levosimendan combined with recombinant human brain natriuretic peptide on diuretic resistance

Ejemplares similares